Whilecarcinogenicity is less of a concern for PPARγ agonists than for PPARα or α/γ dual agonists, the two most prevalenttypes of tumors associated with PPARγ full agonist molecules which do occur are lipomasand hemangiosarcomas. Here, PPARG is linked to angiosarcoma.